AU2015320665B2 - Oncolytic tumor viruses and methods of use - Google Patents

Oncolytic tumor viruses and methods of use Download PDF

Info

Publication number
AU2015320665B2
AU2015320665B2 AU2015320665A AU2015320665A AU2015320665B2 AU 2015320665 B2 AU2015320665 B2 AU 2015320665B2 AU 2015320665 A AU2015320665 A AU 2015320665A AU 2015320665 A AU2015320665 A AU 2015320665A AU 2015320665 B2 AU2015320665 B2 AU 2015320665B2
Authority
AU
Australia
Prior art keywords
protein
modified
adenovirus
adsyn
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015320665A
Other languages
English (en)
Other versions
AU2015320665A1 (en
Inventor
Shigeki MIYAKE-STONER
Clodagh O'shea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Publication of AU2015320665A1 publication Critical patent/AU2015320665A1/en
Priority to AU2022203504A priority Critical patent/AU2022203504B2/en
Application granted granted Critical
Publication of AU2015320665B2 publication Critical patent/AU2015320665B2/en
Priority to AU2025203440A priority patent/AU2025203440A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015320665A 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use Active AU2015320665B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022203504A AU2022203504B2 (en) 2014-09-24 2022-05-24 Oncolytic tumor viruses and methods of use
AU2025203440A AU2025203440A1 (en) 2014-09-24 2025-05-13 Oncolytic tumor viruses and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462054724P 2014-09-24 2014-09-24
US62/054,724 2014-09-24
PCT/US2015/051745 WO2016049201A1 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203504A Division AU2022203504B2 (en) 2014-09-24 2022-05-24 Oncolytic tumor viruses and methods of use

Publications (2)

Publication Number Publication Date
AU2015320665A1 AU2015320665A1 (en) 2017-04-06
AU2015320665B2 true AU2015320665B2 (en) 2022-06-16

Family

ID=55581955

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015320665A Active AU2015320665B2 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use
AU2022203504A Active AU2022203504B2 (en) 2014-09-24 2022-05-24 Oncolytic tumor viruses and methods of use
AU2025203440A Pending AU2025203440A1 (en) 2014-09-24 2025-05-13 Oncolytic tumor viruses and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022203504A Active AU2022203504B2 (en) 2014-09-24 2022-05-24 Oncolytic tumor viruses and methods of use
AU2025203440A Pending AU2025203440A1 (en) 2014-09-24 2025-05-13 Oncolytic tumor viruses and methods of use

Country Status (11)

Country Link
US (1) US20170202893A1 (enExample)
EP (2) EP4043021A3 (enExample)
JP (3) JP6764859B2 (enExample)
KR (3) KR20250081944A (enExample)
CN (1) CN108064275A (enExample)
AU (3) AU2015320665B2 (enExample)
CA (1) CA2961748A1 (enExample)
DK (1) DK3198009T3 (enExample)
ES (1) ES2899913T3 (enExample)
PL (1) PL3198009T3 (enExample)
WO (1) WO2016049201A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
DK3198009T3 (da) * 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
ES2837400T3 (es) * 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) * 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
SG11201906973TA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Multiple transgene recombinant adenovirus
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) * 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
WO2020172509A1 (en) * 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
US20220354911A1 (en) * 2019-09-05 2022-11-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
JP2023513794A (ja) * 2020-02-14 2023-04-03 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｕｌｋ１／２の阻害剤およびその使用方法
AU2021306714A1 (en) * 2020-07-06 2023-02-02 Salk Institute For Biological Studies Oncolytic adenovirus with replication selectivity based on status of p53 transcriptional activity
WO2022236080A2 (en) * 2021-05-06 2022-11-10 Asimov Inc. Compositions and methods for adeno-associated viral production

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ATE546531T1 (de) * 2003-12-31 2012-03-15 Kalobios Inc Transaktivierungssystem für säugerzellen
CA2867129C (en) * 2012-03-13 2023-11-21 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
CA2903582C (en) * 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
WO2012024351A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUERER, C. et al., "Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway", Gene Therapy, (2002), vol. 9, no. 4, pages 270 - 81 *
LOPEZ, M. et al., "A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice", Molecular Therapy, (2012), vol. 20, no. 12, pages 2222 - 33 *

Also Published As

Publication number Publication date
AU2022203504B2 (en) 2025-02-20
JP2017534263A (ja) 2017-11-24
EP4043021A3 (en) 2022-11-23
KR20230165385A (ko) 2023-12-05
EP3198009A1 (en) 2017-08-02
AU2022203504A1 (en) 2022-06-09
JP7416423B2 (ja) 2024-01-17
EP3198009A4 (en) 2018-09-05
JP2024038030A (ja) 2024-03-19
JP6764859B2 (ja) 2020-10-07
KR102608590B1 (ko) 2023-12-01
EP4043021A2 (en) 2022-08-17
KR20250081944A (ko) 2025-06-05
AU2015320665A1 (en) 2017-04-06
EP3198009B1 (en) 2021-09-08
JP2021007392A (ja) 2021-01-28
ES2899913T3 (es) 2022-03-15
WO2016049201A1 (en) 2016-03-31
KR20170063801A (ko) 2017-06-08
KR102814615B1 (ko) 2025-05-28
PL3198009T3 (pl) 2022-01-24
AU2025203440A1 (en) 2025-06-05
CN108064275A (zh) 2018-05-22
DK3198009T3 (da) 2021-11-22
US20170202893A1 (en) 2017-07-20
CA2961748A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
AU2015320665B2 (en) Oncolytic tumor viruses and methods of use
ES2983916T3 (es) Adenovirus armado con acoplador de célula T biespecífica
JP5873893B2 (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
EP4403227A2 (en) Adenovirus armed with bispecific t cell engager (bite)
KR102628234B1 (ko) 알부민-결합 모이어티를 포함하는 아데노바이러스
Huang et al. A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer
JP7394628B2 (ja) 腫瘍溶解性ウイルスおよび方法
AU2013232101A1 (en) Selective cell targeting using adenovirus and chemical dimers
JP2020504767A (ja) 武装した複製可能な腫瘍溶解性アデノウイルス
JP2007511212A (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP5435871B2 (ja) Ｅ１−マイナスアデノウイルス及びその使用
WO2012022496A2 (en) Method for killing tumor stem cells
WO2006075165A1 (en) Combination of oncolytic viruses with angiogenesis inhibitors
Chen et al. Advancing lung cancer treatment with combined c-met promoter-driven oncolytic adenovirus and rapamycin
O'Bryan Generation of an Oncolytic Adenovirus Targeting the CXCR4 and CXCR7 Chemokine Receptors in Breast Cancer
HK40113989A (en) Adenovirus armed with bispecific t cell engager (bite)
Fajardo Calderón Arming oncolytic adenoviruses with bi-specific T-cell engagers to improve antitumor efficacy
EA044599B1 (ru) Аденовирус, вооруженный биспецифическим активатором t-клеток
AU2021303412A1 (en) Recombinant adenovirus genome having a synthetic transcriptional unit and two step transcriptional regulation and amplification
Van Geer Adenovirus targeting for gene therapy of pancreatic cancer
Young A Development of an immunocompetent model of oncolytic adenoviral gene therapy for ovarian cancer.
EA043895B1 (ru) Аденовирус, вооруженный биспецифичным активатором т-клеток

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ O'SHEA, CLODAGH AND MIYAKE-STONER, SHIGEKI

FGA Letters patent sealed or granted (standard patent)